Medicare Part D coverage · 24 · RxCUI 1602588
24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric]
Per the CMS 2026 Part D formulary file, 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric] is covered by 1,240 Medicare Part D plans (24.5% of enrollable products), averaging Tier 3.3, with prior authorization required on 6.9% of covering formularies.
- 24.5%
- Plan coverage
- 1,240
- Plans covering
- T3.3
- Avg tier
- 6.9%
- Prior auth required
What the CMS Formulary Data Shows for 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric]
Per the CMS 2026 Part D formulary file, 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric] (RxNorm concept RXCUI 1602588, generic name 24) appears on 29 distinct formulary files spanning 1,240 Medicare Part D plan offerings - 24.5% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.3.
Real-world access to 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric] depends on utilization management as much as tier placement: 6.9% of covering formularies require prior authorization. 13.8% require step therapy. 20.7% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 21,609 Part D beneficiaries filled 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric] in 2023, with total plan-and-beneficiary spending of $107,814,107 and an average per-beneficiary annual cost of $4,989.31. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric] today.
Coverage Details
- Formularies covering
- 29
- Plans covering
- 1,240
- Coverage rate
- 24.5%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 6.9% of formularies
- Step therapy required
- 13.8% of formularies
- Quantity limits
- 20.7% of formularies
2023 Medicare Spending
- Beneficiaries
- 21,609
- Total spending
- $107,814,107
- Avg per beneficiary
- $4,989.31
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric] covered by Medicare Part D?
Yes, 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric] is covered by 1,240 Medicare Part D plans (24.5% of all Part D formularies).
What tier is 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric] on Medicare Part D plans?
24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric] averages Tier 3.3 across Part D plans, ranging from Tier 1 to Tier 4.
Does 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric] require prior authorization?
6.9% of Part D formularies require prior authorization for 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric]. Step therapy: 13.8%. Quantity limits: 20.7%.
How much does Medicare spend on 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric]?
In 2023, total Medicare Part D spending on 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 14 MG Extended Release Oral Capsule [Namzaric] was $107,814,107, covering 21,609 beneficiaries. The average spend per beneficiary was $4,989.31.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- emtricitabine 10 MG/ML Oral Solution [Emtriva] T3.3
- 200 ACTUAT ipratropium bromide 0.017 MG/ACTUAT Metered Dose Inhaler [Atrovent] T3.3
- progesterone 0.08 MG/MG Vaginal Gel [Crinone] T3.3
- suzetrigine 50 MG Oral Tablet [Journavx] T3.3
- tretinoin 0.0004 MG/MG Topical Gel T3.3
- 0.25 ML leuprolide acetate 30 MG/ML Prefilled Syringe [Eligard] T3.3
Similar prior-authorization rate
- 3.5 ML paliperidone palmitate 312 MG/ML Prefilled Syringe [Invega] 7% PA
- 5 ML paliperidone palmitate 312 MG/ML Prefilled Syringe [Invega] 7% PA
- cilastatin 250 MG / imipenem 250 MG Injection 6.8% PA
- sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro] 7.1% PA
- mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris] 7.1% PA
- paroxetine mesylate 7.5 MG Oral Capsule 7.1% PA